This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. BrainsWay D treatment is FDA cleared for patients with MDD who failed to respond to one or more anti-depressants in the current episode.
David Zacut, MD
Chairman of the Board
Dr. Zacut has served as BrainsWay’s Chairman of the Board of Directors since the company’s inception, and has been providing consulting services to Brain Research Services since May 2001.
Since 1983, Dr. Zacut has been working as a senior practicing physician at Hadassah Hospital, and from 1994 through 2003, he served as a managing director of several large medical centers.
In addition, Dr. Zacut serves as a director of several private companies, including Brain Research Services. Dr. Zacut holds an M.D. degree from the Hebrew University of Jerusalem.